U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ACHIRAL
Molecular Formula C6H5O5S.K
Molecular Weight 228.264
Optical Activity NONE
Defined Stereocenters 0 / 0
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of POTASSIUM DOBESILATE

SMILES

[K+].OC1=CC=C(O)C(=C1)S([O-])(=O)=O

InChI

InChIKey=VKDSBABHIXQFKH-UHFFFAOYSA-M
InChI=1S/C6H6O5S.K/c7-4-1-2-5(8)6(3-4)12(9,10)11;/h1-3,7-8H,(H,9,10,11);/q;+1/p-1

HIDE SMILES / InChI

Description
Curator's Comment: Description was created based on several sources, including https://www.ncbi.nlm.nih.gov/pubmed/7319004 | https://www.ncbi.nlm.nih.gov/pubmed/15312148

Calcium dobesilate (brand name Doxium) is a veno-tonic drug, which is widely prescribed in more than 60 countries from Europe, Latin America, Asia and the Middle East for three main indications: chronic venous disease, diabetic retinopathy and the symptoms of haemorrhoidal attack. This drugs also in the phase III of clinical trial is an effective adjuvant therapy, with an absence of significant side-effects, in patients with venous ulcers and stasis dermatitis. It was suggested, that the inhibitory effect of calcium dobesilate on platelet function is mediated through the cyclic AMP pathway, and probably through activation of adenyl cyclase.

Originator

Sources: Esteve A, Canal J, Laporte J. Ensayo clinico de la accion del 141-E sobre los tiempos de coagulacion y sangria. Medicina Clinica 1959; 33: 249
Curator's Comment: reference retrieved from https://www.ncbi.nlm.nih.gov/pubmed/16772766

Approval Year

TargetsConditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Primary
Doxium

Approved Use

Unknown
Primary
Doxium

Approved Use

Unknown
Primary
Doxium

Approved Use

Unknown
Primary
DICYNONE

Approved Use

ETHAMSYLATE is a haemostatic agent. It reduces bleeding from capillaries. Oral form prescribed for the management of blood loss in menorrhagia. Parenteral form used in surgery: prevention and treatment of pre-, per-, or postsurgical capillary haemorrhages in all delicate operations and in those affecting highly vascularised tissues: E.N.T., gynaecology, obstetrics, urology, odontostomatology, ophthalmology, plastic and reconstructive surgery. It also is used in paediatrics for the prevention of periventricular haemorrhages in premature babies.
PubMed

PubMed

TitleDatePubMed
Effects of etamsylate on platelet functions and arachidonic acid metabolism.
1982 Dec 27
Calcium dobesilate for chronic venous insufficiency: a systematic review.
2004 Mar-Apr
Calcium dobesilate inhibits the alterations in tight junction proteins and leukocyte adhesion to retinal endothelial cells induced by diabetes.
2010 Oct
Patents

Sample Use Guides

Oral. Menorrhagia - The recommended dose is 500 mg 4 times/day during menstruation. Control of hemorrhage after surgery - The recommended dose is 250-500 mg 4-6 hourly as needed. Adults. Presurgical: 1-2 ampoules i.v. or i.m. (250-500mg) 1 hour before surgery. Persurgical: 1-2 ampoules i.v. Repeat the dosage if necessary. Postsurgical: 1-2 ampoules (250-500mg) every 4-6 hours as long as the risk of bleeding persists. Emergency cases, according to the severity of the case: 1-2 ampoules i.v. or i.m. every 4-6 hours as long as the bleeding risk persists. Local treatment: soak a swab with the contents of one ampoule and apply to haemorrhagic area, or in the tooth socket after dental extraction. The application may be repeated if necessary; it may be associated with oral or parenteral administration. Children. Half the adult dose. Neonatology: 10mg per kg body weight (0,1ml=12,5mg) injected intramuscularly within 2 hours of birth then every 6 hours for 4 days.
Route of Administration: Other
Under basal conditions, ethamsylate was unable to modify whole-blood platelet-leukocyte aggregation, but following whole-blood perfusion through a damaged vessel, ethamsylate produced a modest, but significant increase in platelet-leukocyte aggregates at concentrations 20-40 uM
Name Type Language
POTASSIUM DOBESILATE
Common Name English
POTASSIUM HYDROQUINONESULFONATE
Systematic Name English
BENZENESULFONIC ACID, 2,5-DIHYDROXY-, MONOPOTASSIUM SALT
Systematic Name English
POTASSIUM 2,5-DIHYDROXYBENZENESULFONATE
Systematic Name English
BENZENESULFONIC ACID, 2,5-DIHYDROXY-, POTASSIUM SALT (1:1)
Systematic Name English
Code System Code Type Description
CAS
21799-87-1
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY
SMS_ID
300000038842
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY
EPA CompTox
DTXSID8044410
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY
PUBCHEM
23672329
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY
ECHA (EC/EINECS)
244-584-7
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY
FDA UNII
249E3F00EP
Created by admin on Sat Dec 16 08:29:26 GMT 2023 , Edited by admin on Sat Dec 16 08:29:26 GMT 2023
PRIMARY